Single-dose and Steady-state Pharmacokinetics of BIA 2-093 and Its Metabolites in Healthy Elderly Subjects Compared With Those in Healthy Young Subjects

Trial Profile

Single-dose and Steady-state Pharmacokinetics of BIA 2-093 and Its Metabolites in Healthy Elderly Subjects Compared With Those in Healthy Young Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 25 May 2017

At a glance

  • Drugs Eslicarbazepine acetate (Primary)
  • Indications Epilepsy
  • Focus Pharmacokinetics
  • Sponsors Bial
  • Most Recent Events

    • 18 Apr 2017 Status changed from discontinued to completed.
    • 30 Jun 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top